Surveillance reports show increasing NDM-CRE cases in New York City from 2019 to 2024

A surveillance report from New York City documented trends in the annual number of New Delhi metallo-β-lactamase-positive carbapenem-resistant Enterobacterales (NDM-CRE) cases. The report indicated an increase in cases from 2019 to 2024. The specific number of cases, the magnitude of the increase, and detailed demographic information about the affected population were not reported. The report did not describe specific exposures, interventions, or comparators.

No quantitative results, such as absolute case numbers, rates, or statistical measures (e.g., p-values, confidence intervals), were provided. The finding is based on surveillance data, which is observational and descriptive in nature. Safety and tolerability data were not reported, as this was not a clinical trial.

Key limitations include the lack of reported sample size, specific case counts, and any contextual factors that might explain the observed trend. The funding source and potential conflicts of interest were also not reported. The practice relevance is not explicitly stated, but the report serves as a local public health alert. This surveillance signal highlights the need for continued infection control vigilance and diagnostic stewardship for carbapenem-resistant organisms, though the clinical implications are uncertain without more detailed epidemiological data.